Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$35.22 - $51.88 $6.59 Million - $9.7 Million
-187,040 Reduced 81.16%
43,431 $1.82 Million
Q4 2023

Feb 07, 2024

SELL
$22.61 - $40.65 $2.51 Million - $4.51 Million
-110,879 Reduced 32.48%
230,471 $9.14 Million
Q3 2023

Nov 09, 2023

SELL
$25.45 - $37.46 $2.86 Million - $4.21 Million
-112,284 Reduced 24.75%
341,350 $9.39 Million
Q2 2023

Aug 09, 2023

SELL
$30.29 - $38.28 $1.37 Million - $1.73 Million
-45,120 Reduced 9.05%
453,634 $15.4 Million
Q1 2023

May 12, 2023

SELL
$34.78 - $47.43 $80,759 - $110,132
-2,322 Reduced 0.46%
498,754 $17.9 Million
Q4 2022

Feb 09, 2023

SELL
$27.78 - $45.38 $928,935 - $1.52 Million
-33,439 Reduced 6.26%
501,076 $22.3 Million
Q3 2022

Nov 10, 2022

SELL
$22.7 - $37.57 $1.76 Million - $2.91 Million
-77,357 Reduced 12.64%
534,515 $15 Million
Q2 2022

Aug 12, 2022

BUY
$20.5 - $37.33 $400,037 - $728,457
19,514 Added 3.29%
611,872 $16.5 Million
Q1 2022

May 13, 2022

BUY
$27.64 - $39.32 $3.95 Million - $5.61 Million
142,761 Added 31.75%
592,358 $20.2 Million
Q4 2021

Feb 09, 2022

BUY
$35.68 - $56.27 $3.25 Million - $5.12 Million
90,963 Added 25.36%
449,597 $17.4 Million
Q3 2021

Nov 12, 2021

SELL
$28.95 - $55.99 $22,870 - $44,232
-790 Reduced 0.22%
358,634 $19.4 Million
Q2 2021

Aug 12, 2021

BUY
$20.71 - $35.37 $1.16 Million - $1.98 Million
56,072 Added 18.48%
359,424 $12 Million
Q1 2021

May 14, 2021

SELL
$16.19 - $29.91 $73,874 - $136,479
-4,563 Reduced 1.48%
303,352 $6.25 Million
Q4 2020

Feb 25, 2021

BUY
$14.99 - $22.75 $4.62 Million - $7.01 Million
307,915 New
307,915 $5.4 Million

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.15B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.